JP2001516718A5 - - Google Patents

Download PDF

Info

Publication number
JP2001516718A5
JP2001516718A5 JP2000511499A JP2000511499A JP2001516718A5 JP 2001516718 A5 JP2001516718 A5 JP 2001516718A5 JP 2000511499 A JP2000511499 A JP 2000511499A JP 2000511499 A JP2000511499 A JP 2000511499A JP 2001516718 A5 JP2001516718 A5 JP 2001516718A5
Authority
JP
Japan
Prior art keywords
methylpiperazin
tetrahydro
naphthyl
component
morpholinobenzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000511499A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001516718A (ja
Filing date
Publication date
Priority claimed from SE9703375A external-priority patent/SE9703375D0/xx
Application filed filed Critical
Publication of JP2001516718A publication Critical patent/JP2001516718A/ja
Publication of JP2001516718A5 publication Critical patent/JP2001516718A5/ja
Pending legal-status Critical Current

Links

JP2000511499A 1997-09-18 1998-09-09 5−HT再取り込み阻害剤およびh5−HT1Bアンタゴニストまたは部分的アゴニストの組み合わせ Pending JP2001516718A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9703375A SE9703375D0 (sv) 1997-09-18 1997-09-18 A new combination
SE9703375-7 1997-09-18
PCT/SE1998/001601 WO1999013877A1 (en) 1997-09-18 1998-09-09 A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST

Publications (2)

Publication Number Publication Date
JP2001516718A JP2001516718A (ja) 2001-10-02
JP2001516718A5 true JP2001516718A5 (cg-RX-API-DMAC10.html) 2006-01-05

Family

ID=20408295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000511499A Pending JP2001516718A (ja) 1997-09-18 1998-09-09 5−HT再取り込み阻害剤およびh5−HT1Bアンタゴニストまたは部分的アゴニストの組み合わせ

Country Status (29)

Country Link
US (1) US6159971A (cg-RX-API-DMAC10.html)
EP (1) EP1014985B1 (cg-RX-API-DMAC10.html)
JP (1) JP2001516718A (cg-RX-API-DMAC10.html)
KR (1) KR20010024076A (cg-RX-API-DMAC10.html)
CN (1) CN1195519C (cg-RX-API-DMAC10.html)
AR (1) AR015448A1 (cg-RX-API-DMAC10.html)
AT (1) ATE240733T1 (cg-RX-API-DMAC10.html)
AU (1) AU752722B2 (cg-RX-API-DMAC10.html)
BR (1) BR9812088A (cg-RX-API-DMAC10.html)
CA (1) CA2302382A1 (cg-RX-API-DMAC10.html)
DE (1) DE69814882T2 (cg-RX-API-DMAC10.html)
DK (1) DK1014985T3 (cg-RX-API-DMAC10.html)
EE (1) EE04141B1 (cg-RX-API-DMAC10.html)
ES (1) ES2200370T3 (cg-RX-API-DMAC10.html)
HU (1) HUP0200602A3 (cg-RX-API-DMAC10.html)
IL (1) IL134776A0 (cg-RX-API-DMAC10.html)
IS (1) IS5406A (cg-RX-API-DMAC10.html)
MY (1) MY116280A (cg-RX-API-DMAC10.html)
NO (1) NO20001399L (cg-RX-API-DMAC10.html)
NZ (1) NZ503171A (cg-RX-API-DMAC10.html)
PL (1) PL339371A1 (cg-RX-API-DMAC10.html)
PT (1) PT1014985E (cg-RX-API-DMAC10.html)
RU (1) RU2214824C2 (cg-RX-API-DMAC10.html)
SE (1) SE9703375D0 (cg-RX-API-DMAC10.html)
SK (1) SK2852000A3 (cg-RX-API-DMAC10.html)
TR (1) TR200000727T2 (cg-RX-API-DMAC10.html)
TW (1) TW589183B (cg-RX-API-DMAC10.html)
WO (1) WO1999013877A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA987817B (cg-RX-API-DMAC10.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
WO2002066454A1 (fr) * 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
CA2445843A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
SE0203778D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
AR047553A1 (es) 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
KR100511288B1 (ko) * 2003-11-14 2005-08-31 엘지전자 주식회사 4대의 압축기를 구비한 공기조화기의 실외기
US20060217394A1 (en) * 2005-02-23 2006-09-28 Silvan S. Tomkins Institute, Inc. Treatment of anhedonia
CA2617546C (en) 2005-08-03 2014-07-15 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
FR2890862B1 (fr) * 2005-09-19 2008-01-25 Sanofi Aventis Sa Association d'agoniste aux recepteurs beta 3 et d'inhibiteur de la recapture de monoamnies, compostion pharmaceutique la contenant et son utilisation en therapeutique.
WO2007048803A1 (en) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
RU2477634C2 (ru) * 2006-06-16 2013-03-20 Теракос, Инк. Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
CA2660476C (en) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
WO2008022932A2 (en) 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
ES2162792T3 (es) * 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
SE9703374D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination

Similar Documents

Publication Publication Date Title
RU2214824C2 (ru) Комбинация ингибитора обратного захвата 5-ht и антагониста или частичного агониста h5-ht1b
JP2001516719A5 (cg-RX-API-DMAC10.html)
RU2000109563A (ru) Комбинация обратного поглощения 5-нт селективного антагониста или частичного агониста н5-нт1b
JP2008538741A (ja) 鬱病の治療用及び/又は予防用の医薬組成物
JP2004538259A5 (cg-RX-API-DMAC10.html)
JP2009526821A (ja) 注意欠陥多動性障害治療用の新規な医薬組成物
JP2005501120A5 (cg-RX-API-DMAC10.html)
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
JP2008531715A (ja) 統合失調症及び関連疾患の治療用及び/又は予防用の医薬組成物
JP2003528917A5 (cg-RX-API-DMAC10.html)
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
RU2006101458A (ru) 2-аминобензотиазолы в качестве обратных агонистов рецепторов cb1
JP4800936B2 (ja) ヒスタミンレセプターh3のアンタゴニスト又は逆アゴニスト及び抗生精神病又は抗うつ病剤を含んで成る組み合わせ産物、並びにそれらの抗精神薬の不都合な効果を予防する医薬を調製するための使用
JP2008511569A (ja) 注意欠如活動過多障害の治療方法
TW201912153A (zh) 用於治療b型肝炎的化合物、醫藥組合物及方法
AR013503A1 (es) Una combinacion de un inhibidor de la monoamina oxidasa y un antagonista o agonista parcial selectivo de h5-ht(1b), formulacion farmaceutica, usos ymetodo de preparacion
JP2001516717A5 (cg-RX-API-DMAC10.html)
RU2006113691A (ru) Применение 4-анилин-3-хинолинкарбонитрилов для лечения хронической миелогенной лейкемии (cml)
RU2215528C2 (ru) Комбинация селективного антагониста 5-нт1a и селективного антагониста или частичного агониста н5-нт1b
RU2000109558A (ru) Комбинация селективного антагониста 5-нт1a и селективного антагониста или частичного агониста н5-нт1b
RU2007101522A (ru) Диарилметилпиперазиновые производные, их получение и применение
RU2005135649A (ru) Комбинации пароксетина и 4-(s)-(4-ацетилпиперазин-1-ил)-2-(r)-(4-фтор-2-метилфенил)пиперидин-1-карбоновой кислоты [1-(r)-(3, 5-бис-трифторметилфенил)этил]метиламида для лечения депрессии и/или тревоги
JP2004504377A5 (cg-RX-API-DMAC10.html)
DOP2005000085A (es) Composicion farmaceutica antimicobacterial
RU2000109560A (ru) Комбинация ингибитора моноаминоксидазы и селективного антагониста или частичного агониста н5-нт1b